Meryx
Chapel Hill
About Meryx
Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancers such as leukemia, lung cancer, and melanoma. It offers potent inhibitors of MerTK, such as MRX-2843, a clinical drug candidate; and MRX-6313, a backup candidate that inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies. Meryx was founded in 2013 and is based in Chapel Hill, North Carolina.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.6M
- Funding stage: M&A
- Last round: Debt Financing (Jun 2015)
- Website: meryxpharma.com
- Phone: (919) 985-7821
Industries & Categories
Biotechnology, Medical, Medical Device
Canonical: https://fsome.com/organization/meryx-2439160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.